Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Transgene

< Previous 1 2 Next >
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
From Transgene
Via Business Wire
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
From Transgene
Via Business Wire
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
From Transgene
Via Business Wire
Transgene Announces Upcoming Investor Meetings
From Transgene
Via Business Wire
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®
From Transgene
Via Business Wire
Transgene and BioInvent Announce Positive Progress for BT-001
From Transgene
Via Business Wire
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
From Transgene
Via Business Wire
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
From Transgene
Via Business Wire
Transgene’s Combined General Meeting of May 25, 2022
From Transgene
Via Business Wire
Transgene Announces Upcoming Investor Meetings
From Transgene
Via Business Wire
Transgene: Q1 2022 Financial Position and Business Update
From Transgene
Via Business Wire
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
From Transgene
Via Business Wire
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
From Transgene
Via Business Wire
Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
From Transgene
Via Business Wire
Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022
From Transgene
Via Business Wire
Transgene Appoints Steven Bloom as Chief Business Officer
From Transgene
Via Business Wire
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade
From Transgene
Via Business Wire
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
From Transgene
Via Business Wire
Transgene Announces Financial Calendar for 2022
From Transgene
Via Business Wire
Transgene Announces Investor Meetings for January 2022
From TRANSGENE
Via Business Wire
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
From Transgene
Via Business Wire
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
From Transgene
Via Business Wire
Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
From Transgene
Via Business Wire
Transgene Reports Business Update and Q3 2021 Financial Position
From Transgene
Via Business Wire
Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
From Transgene
Via Business Wire
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
From Transgene
Via Business Wire
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
From Transgene
Via Business Wire
Transgene Announces Upcoming Investor Meetings
From Transgene
Via Business Wire
Transgene Participates in New Cancer Research Consortium
From Transgene
Via Business Wire
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
From Transgene
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.